ArticleBiomarker insights2026
Urinary Calprotectin Predicts Severe Acute Kidney Injury After Non-cardiac Surgery in Surgical Intensive Care Unit: A Prospective Cohort Study.
Article in Biomarker insights, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative risk stratification for severe acute kidney injury (AKI) can facilitate timely intervention and improve prognosis. Objectives: This study aimed to evaluate the added predictive ability of urinary calprotectin for postoperative risk stratification of severe AKI in non-cardiac surgery patients. Design: A total of 580 patients were enrolled, and 98 (17%) developed severe AKI with a median time of 12.8 hours after SICU admission. Methods: In a prospective cohort of patients transferred to the surgical intensive care unit (SICU) after non-cardiac surgery, calprotectin was measured in urine samples collected 0, 6, and 12 hours after SICU admission. A clinical model for predicting severe AKI was established. We tested the ability of urinary calprotectin alone to predict severe AKI by area under the receiver operating characteristics curve (AUC) analysis. We further evaluated the improvement of the pre-diction ability after adding urinary calprotectin in the clinical model by the increment in AUC, relevant integrated discrimination improvement (IDI), and net reclassification improvement (NRI). Results: Higher urinary calprotectin levels were observed in the severe AKI group at any time point (All P<0.001). In the entire cohort, the AUC of urinary calprotectin at SICU admission for predicting severe AKI was 0.701(95% CI, 0.649 to 0.754), and calprotectin ≥32.3 ng/ml was associated with increased risk (OR 6.119, 95% CI 3.259 - 11.488). The AUC of the clinical model increased from 0.693 (95%CI, 0.633 to 0.754) to 0.730 (95%CI, 0.677 to 0.784) upon adding urinary calprotectin, the NRI was 0.337 (P<0.001) and the IDI was 0.055 (P<0.001). Conclusion: A combination of urinary calprotectin and clinical features could be useful for postoperative risk stratification of severe AKI in non-cardiac surgery patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.